Apple (AAPL), Oscar Health (OSCR) and Eli Lilly (LLY) all climbed to fresh 52-week highs on Monday, driven by distinct catalysts across technology and healthcare sectors. Apple reached an all-time high of $317.40 following its unveiling of Siri AI powered by Google Gemini technology at its Worldwide Developers Conference, Oscar Health hit a five-year high of $27.59 after reaffirming its 2026 revenue forecast of $18.7 billion to $19 billion, and Eli Lilly touched a record $1,182.73 after reporting positive late-stage trial results for its oral obesity drug Foundayo. The simultaneous rallies reflected investor confidence in AI integration, healthcare business execution and clinical trial outcomes.
Apple Unveils Siri AI Powered by Google Gemini at WWDC
At its Worldwide Developers Conference, Apple unveiled "Siri AI," a revamped AI assistant powered in part by Google Gemini technology. The upgraded assistant is built to work across Apple devices and to handle more complex tasks and user requests.
The new assistant can search through messages, emails, photos and other content to help users locate information more efficiently. Siri AI can also respond to questions about content displayed on a device's screen and perform actions across applications, including creating emails, editing images and organizing information.
Users can access Siri AI through iPhone, iPad, Mac, Apple Watch, CarPlay, AirPods and Apple Vision Pro. Following the launch, Apple stock reached an all-time high of $317.40 and reversed course to end Monday's session over 1% lower.
Oscar Health Reaffirms 2026 Revenue Guidance of $18.7-19 Billion
Oscar Health shares drew interest after the company reaffirmed its 2026 revenue guidance of $18.7 billion to $19 billion. CFO R. Scott Blackley said the 2026 fiscal year has started on a strong footing, supported by stable membership trends, favorable healthcare utilization patterns and better-than-expected industry data.
"We did file an 8-K this morning and just reaffirmed our full-year guidance. But behind that affirmation of our current guidance, we do see some pretty healthy tailwinds in the performance of the company," Blackley said.
Oscar Health stock hit a five-year high of $27.59 on Monday.
Eli Lilly Reports Positive Foundayo Trial Results Across Three Studies
Eli Lilly stock hit a record high of $1,182.73 on Monday after the company reported positive late-stage trial results for Foundayo, its recently approved oral obesity treatment.
The company unveiled detailed results from three late-stage clinical studies showing that its oral GLP-1 medicine Foundayo (orforglipron) delivered stronger blood sugar control and greater weight reduction than several competing treatments for adults with Type 2 diabetes.
Eli Lilly said Foundayo achieved favorable outcomes across the ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5 studies, including a head-to-head comparison against oral semaglutide. Lilly also announced plans to seek U.S. regulatory approval for the drug as a treatment for Type 2 diabetes before the end of the second quarter.
Foundayo is already approved in the U.S. for weight management. So far this year, AAPL and LLY stocks have gained nearly 9% and 7%, while OSCR stock has surged 90%.
FAQ
What did Apple announce at WWDC on Monday?
Apple unveiled "Siri AI," a revamped AI assistant powered in part by Google Gemini technology. The upgraded assistant works across Apple devices including iPhone, iPad, Mac, Apple Watch, CarPlay, AirPods and Apple Vision Pro, and can search through messages, emails, photos and other content, respond to on-screen questions, and perform actions across applications.
Why did Oscar Health stock reach a five-year high?
Oscar Health stock hit a five-year high of $27.59 on Monday after the company reaffirmed its 2026 revenue guidance of $18.7 billion to $19 billion. CFO R. Scott Blackley cited stable membership trends, favorable healthcare utilization patterns and better-than-expected industry data as factors supporting the 2026 fiscal year performance.
What trial results did Eli Lilly report for Foundayo?
Eli Lilly reported positive late-stage trial results from three clinical studies (ACHIEVE-2, ACHIEVE-3 and ACHIEVE-5) showing that Foundayo (orforglipron) delivered stronger blood sugar control and greater weight reduction than several competing treatments for adults with Type 2 diabetes, including a head-to-head comparison against oral semaglutide. The company announced plans to seek U.S. regulatory approval for the drug as a Type 2 diabetes treatment before the end of the second quarter.
